Redwood Wealth Management Group LLC Purchases 124 Shares of Johnson & Johnson (NYSE:JNJ)

Redwood Wealth Management Group LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,020 shares of the company’s stock after acquiring an additional 124 shares during the period. Redwood Wealth Management Group LLC’s holdings in Johnson & Johnson were worth $580,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in JNJ. Bay Harbor Wealth Management LLC bought a new position in shares of Johnson & Johnson during the 4th quarter valued at $32,000. E. Ohman J or Asset Management AB boosted its position in Johnson & Johnson by 12.1% during the fourth quarter. E. Ohman J or Asset Management AB now owns 109,740 shares of the company’s stock valued at $15,871,000 after buying an additional 11,840 shares during the period. James J. Burns & Company LLC grew its stake in shares of Johnson & Johnson by 13.3% during the fourth quarter. James J. Burns & Company LLC now owns 8,609 shares of the company’s stock valued at $1,245,000 after buying an additional 1,012 shares during the last quarter. Mather Group LLC. lifted its stake in shares of Johnson & Johnson by 1.8% in the 4th quarter. Mather Group LLC. now owns 131,844 shares of the company’s stock valued at $19,067,000 after acquiring an additional 2,315 shares during the last quarter. Finally, Stephens Consulting LLC boosted its holdings in Johnson & Johnson by 9.2% during the 4th quarter. Stephens Consulting LLC now owns 4,143 shares of the company’s stock valued at $599,000 after acquiring an additional 349 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $153.10 on Friday. The stock has a market cap of $368.61 billion, a PE ratio of 23.02, a price-to-earnings-growth ratio of 2.44 and a beta of 0.52. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The company’s fifty day moving average price is $147.46 and its 200-day moving average price is $156.06.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company’s revenue was up 5.3% on a year-over-year basis. During the same period last year, the company earned $2.29 earnings per share. On average, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.24%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of analyst reports. Argus raised Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Wolfe Research assumed coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 price target for the company. Wells Fargo & Company cut their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Finally, Morgan Stanley cut their target price on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $170.67.

Insider Activity

In other news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.